EXOZYMES INC. Depreciation
EXOZYMES INC. (EXOZ) reported Depreciation of $151.10 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-08-13
- EXOZYMES INC. depreciation for the quarter ending 2026-06-30 was $76.95K, a 6.49% increase year-over-year.
- EXOZYMES INC. depreciation for the quarter ending 2026-03-31 was $74.15K, a 5.17% increase year-over-year.
- EXOZYMES INC. depreciation for the quarter ending 2025-12-31 was $73.60K, a 8.93% increase year-over-year.
- EXOZYMES INC. depreciation for the quarter ending 2025-09-30 was $71.60K, a 3.96% increase year-over-year.
- EXOZYMES INC. depreciation for fiscal 2025 was $287.96K, a 7.70% increase from fiscal 2024.
- EXOZYMES INC. depreciation for fiscal 2024 was $267.38K, a 35.77% increase from fiscal 2023.
- EXOZYMES INC. depreciation for fiscal 2023 was $196.94K.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|
| 2026-06-30 | $76.95K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $151.10K 10-Q · filed 2026-08-13 | $224.69K derived: sum of 3 quarters · filed 2026-08-13 | $296.30K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $74.15K 10-Q · filed 2026-05-14 | $147.75K derived: sum of 2 quarters · filed 2026-05-14 | $219.35K derived: sum of 3 quarters · filed 2026-05-14 | $291.61K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $73.60K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $145.20K derived: sum of 2 quarters · filed 2026-03-30 | $217.46K derived: sum of 3 quarters · filed 2026-08-13 | $287.96K 10-K · filed 2026-03-30 |
| 2025-09-30 | $71.60K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $143.86K derived: sum of 2 quarters · filed 2026-08-13 | $214.36K 10-Q · filed 2025-11-13 | $281.93K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $72.26K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $142.76K 10-Q · filed 2026-08-13 | $210.33K derived: sum of 3 quarters · filed 2026-08-13 | $279.20K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $70.50K 10-Q · filed 2026-05-14 | $138.07K derived: sum of 2 quarters · filed 2026-05-14 | $206.95K derived: sum of 3 quarters · filed 2026-05-14 | $275.09K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $67.57K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $136.44K derived: sum of 2 quarters · filed 2026-03-30 | $204.59K derived: sum of 3 quarters · filed 2026-03-30 | $267.38K 10-K · filed 2026-03-30 |
| 2024-09-30 | $68.88K 10-Q · filed 2024-11-12 | $137.02K derived: sum of 2 quarters · filed 2025-08-12 | $199.81K 10-Q · filed 2025-11-13 | $258.78K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-06-30 | $68.14K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $130.94K 10-Q · filed 2025-08-12 | $189.90K derived: sum of 3 quarters · filed 2025-08-12 | $239.63K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $62.79K 10-Q · filed 2025-05-12 | $121.76K derived: sum of 2 quarters · filed 2025-05-12 | $171.48K derived: sum of 3 quarters · filed 2025-05-12 | |
| 2023-12-31 | $58.97K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $108.69K derived: sum of 2 quarters · filed 2025-03-31 | $196.94K 10-K · filed 2025-03-31 | |
| 2023-09-30 | $49.72K 10-Q · filed 2024-11-12 | $137.97K 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |